Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Human Chorionic Gonadotropin (HCG) Market size was valued at USD 790.19 million in 2024 and is likely to cross USD 1.81 billion by 2037, registering more than 6.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of human chorionic gonadotropin is estimated at USD 834.52 million.
The increasing infertility rate globally, along with the growing investment in the innovation of technologically improved products are expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing awareness among the population towards gynaecological problems and the rising middle-class population in the emerging economies on a global level. According to the data collected from the World Health Organization (WHO), in September 2020, approximately 48 million couples and 186 million individuals across the globe lives with infertility. Such increasing number of infertility rate has rapidly increased the requirement for human chorionic gonadotropin (HCG) in the market. The rising shift of traditional lifestyles to western lifestyle adoption along with poor dietary habits among individuals are expected to make a significant contribution to the soaring revenue of the human chorionic gonadotropin (HCG) market. Gynaecology is one of the important branch of medicine concerned with medical issues among women. As a result, it includes conditions associated to wellbeing of women and their testing and screening methodology. Women’s body is predominantly prone to various types of cancer, including, breast cancer, cervical cancer, and ovarian cancer. Other rising medical conditions such as polycystic ovarian disorder, infertility, menopause, depression, osteoporosis, and obesity. Human chorionic gonadotropin (hGC) is a hormone produced by placenta in a pregnant women and is a type of gonadotropin hormone.
Human Chorionic Gonadotropin (HCG) Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Cases of Infertility
- Increasing in the Incidence of Male Hypogonadism
Challenges
- Regulations & Warnings Issued by FDA
- Lack of Accuracy & Specificity
Human Chorionic Gonadotropin (HCG) Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.6% |
|
Base Year Market Size (2024) |
USD 790.19 million |
|
Forecast Year Market Size (2037) |
USD 1.81 billion |
|
Regional Scope |
|
Human Chorionic Gonadotropin (HCG) Segmentation
The human chorionic gonadotropin (HCG) market is segmented based on technology into natural source extraction, and recombinant technology, out of which, natural source extraction segment is anticipated to grab the largest share by the end of 2021 on account of increased number investments by the major players to extract gonadotropins from natural source. However, increasing government approval of digital devices globally is also projected to contribute to the growth of the recombinant technology segment is expected to increase with a rapid growth rate on the back of increasing availability of recombinant hCGs during the forecast period.
Based on therapeutic area, the female infertility segment held the largest share in the global Human chorionic gonadotropin (HCG) market on the back of growing concern and awareness for infertility among the couples and individuals across the developing and under-developed countries.
Our in-depth analysis of the global market includes the following segments
|
By Technology |
|
|
By Therapeutic Area |
|
|
By End-User
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportHuman Chorionic Gonadotropin (HCG) Industry - Regional Synopsis
APAC Market Statistics
Geographically, the human chorionic gonadotropin (HCG) market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. Asia Pacific industry is poised to hold largest revenue share by 2037, owing to growing population, increasing concern and awareness among the individuals in the region.
North America Market Analysis
Furthermore, in 2021, the human chorionic gonadotropin (HCG) market in North America is evaluated to occupy the largest share in terms of revenue, owing to the increasing incidence of infertility among the women aged between 15-44 years in the region. According to the report published by the Centers for Disease Control and Prevention (CDC), annually approximately 10% of the women which accounts for 6.1 million in the United States face difficulty to conceive or staying pregnant. Such increasing issues during the reproductive age among the individuals and couples is further expected to drive the demand for Human chorionic gonadotropin (HCG) in the North American countries. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global Human chorionic gonadotropin (HCG) market on account of its proven success in terms of technology development in the region.
Companies Dominating the Human Chorionic Gonadotropin (HCG) Landscape
- Merck & Co.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cigna
- Lee BioSolutions
- Swiss Precision Diagnostics GmbH
- Abbott Laboratories
- Quidel Corporation
- Geratherm Medical AG
- bioMérieux SA
- CIGA Healthcare Ltd
In the News
- May 2020: Tolmar Inc., one of the leading pharmaceutical company in the U.S., announced that the U.S. Food and Drug Administration (FDA) has approved their drug application for FENSOLVI, which is a leuprolide acetate for injectable suspension to treat pediatric patients with two years of age and older with central gonadotropin-dependent precocious puberty (CPP).
- January 2019: Ferring Pharmaceuticals based in Switzerland, announced that they have strategically acquired the United States commercialization rights for generic Ganirelix Acetate Injection to prevent premature ovulation in women undergoing fertility treatment.
Author Credits: Radhika Pawar
- Report ID: 3160
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
